References

Key articles

Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849-862.

Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(suppl 3):S810-S816.

WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-1495.

WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-1495.

Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292-1299.

Lado M, Walker N, Baker P, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015;15:1024-1033.

Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-737.

Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-737.

Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292-1299.

World Health Organization. Manual for the care and management of patients in Ebola care units/community care centres: interim emergency guidance. January 2015. http://www.who.int/ (last accessed 19 July 2017).

World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. February 2016. http://apps.who.int/ (last accessed 19 July 2017).

World Health Organization. Interim guidance: potential Ebola therapies and vaccines. November 2014. http://apps.who.int/ (last accessed 19 July 2017).

World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. February 2016. http://apps.who.int/ (last accessed 19 July 2017).

World Health Organization. Interim guidance: potential Ebola therapies and vaccines. November 2014. http://apps.who.int/ (last accessed 19 July 2017).

Reference articles

1.  Centers for Disease Control and Prevention. About Ebola virus disease. February 2016. http://www.cdc.gov/ (last accessed 19 July 2017).

2.  World Health Organization. Ebola virus disease fact sheet. February 2018 [internet publication].

3.  WHO Ebola Response Team. Ebola virus disease among children in West Africa. N Engl J Med. 2015;372:1274-1277.

4.  Kuhn JH, Andersen, KG, Baize, S, et al. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses. 2014;6:4760-4799.

5.  Centers for Disease Control and Prevention. Ebola fact sheet. August 2015. http://www.cdc.gov/ (last accessed 19 July 2017).

6.  Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-976.

7.  Maganga GD, Kapetshi J, Berthet N, et al. Ebola virus disease in the Democratic Republic of Congo. N Engl J Med. 2014;371:2083-2091.

8.  Formenty P, Hatz C, Le Guenno B, et al. Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation. J Infect Dis. 1999;179(suppl 1):S48-S53.

9.  Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One. 2012;7:e52986.

10.  Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849-862.

11.  Barrette RW, Metwally SA, Rowland JM, et al. Discovery of swine as a host for the Reston ebolavirus. Science. 2009;325:204-206.

12.  Swanepoel R, Smit SB, Rollin PE, et al. Studies of reservoir hosts for Marburg virus. Emerg Infect Dis. 2007;13:1847-1851.

13.  McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210:558-566.

14.  Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487-498.

15.  Yan T, Mu J, Qin E, et al. Clinical characteristics of 154 patients suspected of having Ebola disease in the Ebola holding centre of Jui government hospital in Sierra Leone during the 2014 Ebola outbreak. Eur J Microbiol Infect Dis. 2015;34:2089-2095.

16.  Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(suppl 3):S810-S816.

17.  Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis. 1999;179(suppl 1):S1-S7.

18.  WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-1495.

19.  Dallatomasinas S, Crestani R, Squire JS, et al. Ebola outbreak in rural West Africa: epidemiology, clinical features and outcomes. Trop Med Int Health. 2015;20:448-454.

20.  Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40-47.

21.  Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa - clinical manifestations and management. N Engl J Med. 2014;371:2054-2057.

22.  Schieffelin JS, Shaffer JG, Goba A, et al; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092-2100.

23.  Nkoghe D, Leroy EM, Toung-Mve M, et al. Cutaneous manifestations of filovirus infections. Int J Dermatol. 2012;51:1037-1043.

24.  Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271-293.

25.  Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis. 2004;10:40-47.

26.  Centers for Disease Control and Prevention. CDC laboratories produce first genomic sequence of Liberian Ebola. August 2015. http://www.cdc.gov/ (last accessed 19 July 2017).

27.  World Health Organization. Ebola virus disease – Democratic Republic of the Congo. Disease outbreak news: update. 11 July 2019 [internet publication].

28.  World Health Organization. Ebola virus disease - Republic of Uganda. Disease outbreak news. 13 June 2019 [internet publication].

29.  Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-976.

30.  WHO Ebola Response Team. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481-1495.

31.  Ansumana R, Jacobsen KH, Idris M, et al. Ebola in Freetown area, Sierra Leone - a case study of 581 patients. N Engl J Med. 2015;372:587-588.

32.  New York Times. How many Ebola patients have been treated outside of Africa? January 2015. http://www.nytimes.com/ (last accessed 19 July 2017).

33.  Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One. 2012;7:e52986.

34.  World Health Organization. Are the Ebola outbreaks in Nigeria and Senegal over? October 2014. http://www.who.int/ (last accessed 19 July 2017).

35.  Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis. 1999;179(suppl 1):9-16.

36.  Swanepoel R, Leman PA, Burt FJ, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis. 1996;2:321-325.

37.  Reiter P, Turell M, Coleman R, et al. Field investigations of an outbreak of Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: arthropod studies. J Infect Dis. 1999;179(suppl 1):S148-S154.

38.  Pigott DM, Golding N, Mylne A, et al. Mapping the zoonotic niche of Ebola virus disease in Africa. Elife. 2014;3:e04395.

39.  Dowell SF, Mukunu R, Ksiazek TG, et al. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis. 1999;179(suppl 1):S87-S91.

40.  Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271-293.

41.  Osterholm MT, Moore KA, Kelley NS, et al. Transmission of Ebola viruses: what we know and what we do not know. MBio. 2015;6:e00137.

42.  Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394-2401.

43.  World Health Organization. Sierra Leone: a traditional healer and a funeral. 2014. http://www.who.int/ (last accessed 19 July 2017).

44.  Lau MS, Dalziel BD, Funk S, et al. Spatial and temporal dynamics of superspreading events in the 2014-2015 West Africa Ebola epidemic. Proc Natl Acad Sci U S A. 2017;114:2337-2342.

45.  Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196(suppl 2):S142-S147.

46.  Emond RT, Evans B, Bowen ET, et al. A case of Ebola virus infection. Br Med J. 1977;2:541-544.

47.  Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis. 1999;179(suppl 1):S28-S35.

48.  World Health Organization. Clinical care for survivors of Ebola virus disease: interim guidance. April 2016 [internet publication].

49.  Rogstad KE, Tunbridge A. Ebola virus as sexually transmitted infection. Curr Opin Infect Dis. 2015;28:83-85.

50.  Sonnenberg P, Field P. Sexual and mother-to-child transmission of Ebola virus in the post-convalescent period. Clin Infect Dis. 2015;60:974-975.

51.  Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med. 2015;373:2448-2454.

52.  Crozier I. Ebola virus RNA in the semen of male survivors of Ebola virus disease: the uncertain gravitas of a privileged persistence. J Infect Dis. 2016;214:1467-1469.

53.  Thorson A, Formenty P, Lofthouse C, et al. Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations. BMJ Open. 2016;6:e008859.

54.  Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179(suppl 1):S170-S176.

55.  Judson S, Prescott J, Munster V. Understanding Ebola virus transmission. Viruses. 2015;7:511-521.

56.  Beeching NJ, Fletcher TE, Hill DR, et al. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents. 2010;36(suppl 1):S26-S35.

57.  Carroll M, Matthews DA, Hiscox JA, et al. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature. 2015;524:97-101.

58.  Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345:1369-1372.

59.  Sharma N, Cappell MS. Gastrointestinal and hepatic manifestations of Ebola virus infection. Dig Dis Sci. 2015;60:2590-2603.

60.  Ramanan P, Shabman RS, Brown CS, et al. Filoviral immune evasion mechanisms. Viruses. 2011;3:1634-1649.

61.  Ramanan P, Edwards MR, Shabman RS, et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A. 2012;109:20661-20666.

62.  Ansari AA. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014;55:1-9.

63.  Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015;235:153-174.

64.  Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22:1250-1259.

65.  Fletcher T, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med. 2014;40:1936-1939.

66.  Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol. 2004;78:10370-10377.

67.  Rougeron V, Feldmann H, Grard G, et al. Ebola and Marburg haemorrhagic fever. J Clin Virol. 2015;64:111-119.

68.  Zapata JC, Cox D, Salvato MS. The role of platelets in the pathogenesis of viral hemorrhagic fevers. PLoS Negl Trop Dis. 2014;8:e2858.

69.  Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210-2215.

70.  Ruibal P, Oestereich L, Lüdtke A, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100-104.

71.  Nielsen CF, Kidd S, Sillah AR, et al. Improving burial practices and cemetery management during an Ebola virus disease epidemic - Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:20-27.

72.  Georges-Courbot MC, Sanchez A, Lu CY, et al. Isolation and phylogenetic characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis. 1997;3:59-62.

73.  Strauss S. Ebola research fueled by bioterrorism threat. CMAJ. 2014;186:1206.

74.  Centers for Disease Control and Prevention. Guidance on personal protective equipment to be used by healthcare workers during management of patients with confirmed Ebola or persons under investigation for Ebola who are clinically unstable or have bleeding, vomiting, or diarrhea in US hospitals, including procedures for donning and doffing PPE. August 2015. http://www.cdc.gov/ (last accessed 19 July 2017).

75.  Jacobs M, Aarons E, Bhagani S, et al. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis. 2015;15:1300-1304.

76.  Kanapathipillai R, Henao Restrepo AM, Fast P, et al. Ebola vaccine - an urgent international priority. N Engl J Med. 2014;371:2249-2251.

77.  Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ. 2014;349:g5079.

78.  Centers for Disease Control and Prevention. Case definition for Ebola virus disease (EVD). November 2014. http://www.cdc.gov/ (last accessed 19 July 2017).

79.  Mendelson M, Han PV, Vincent P, et al. Regional variation in travel-related illness acquired in Africa, March 1997-May 2011. Emerg Infect Dis. 2014;20:532-541.

80.  Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292-1299.

81.  World Health Organization. Case definition recommendations for Ebola or Marburg virus diseases. August 2014. http://www.who.int/ (last accessed 19 July 2017).

82.  Petrosillo N, Nicastri E, Lanini S, et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis. 2015;15:432.

83.  Cournac JM, Karkowski L, Bordes J, et al. Rhabdomyolysis in Ebola virus disease. Results from an observational study in a treatment centre in Guinea. Clin Infect Dis. 2016;62:19-23.

84.  Lado M, Walker N, Baker P, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis. 2015;15:1024-1033.

85.  Glynn JR. Age-specific incidence of Ebola virus disease. Lancet. 2015:386;432.

86.  Mupere E, Kaducu OF, Yoti Z. Ebola haemorrhagic fever among hospitalised children and adolescents in northern Uganda: epidemiologic and clinical observations. Afr Health Sci. 2001;1:60-65.

87.  Peacock G, Uyeki TM, Rasmussen SA. Ebola virus disease and children: what pediatric health care professionals need to know. JAMA Pediatr. 2014;168:1087-1088.

88.  Fitzgerald F, Naveed A, Wing K, et al. Ebola virus disease in children, Sierra Leone, 2014-2015. Emerg Infect Dis. 2016 Oct;22(10):1769-77.

89.  Shah T, Greig J, van der Plas LM, et al. Inpatient signs and symptoms and factors associated with death in children aged 5 years and younger admitted to two Ebola management centres in Sierra Leone, 2014: a retrospective cohort study. Lancet Glob Health. 2016 Jul;4(7):e495-501.

90.  Dananché C, Bénet T, Vanhems P. Ebola: fever definitions might delay detection in non-epidemic areas. Lancet. 2014;384:1743.

91.  Lado M, Howlett P. Ebola virus disease in children: towards a better clinical picture and improved management. Lancet Glob Health. 2016 Jul;4(7):e436-7.

92.  Lópaz MA, Amela C, Ordobas M, et al; Working group of Ebola outbreak investigation team of Madrid. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Euro Surveill. 2015;20:21003.

93.  Lyon GM, Mehta AK, Varkey JB, et al; Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402-2409.

94.  World Health Organization. Exit screening at airports, ports and land crossings: interim guidance for Ebola virus disease. November 2014 [internet publication].

95.  World Health Organization. Laboratory diagnosis of Ebola virus disease: interim guidance. September 2014. http://www.who.int/ (last accessed 19 July 2017).

96.  Cherpillod P, Schibler M, Vieille G, et al. Ebola virus disease diagnosis by real-time RT-PCR: a comparative study of 11 different procedures. J Clin Virol. 2016;77:9-14.

97.  Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330-4341.

98.  Boggild AK, Esposito DH, Kozarsky PE, et al. Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network. Ann Intern Med. 2015;62:757-764.

99.  McElroy AK, Erickson BR, Flietstra TD, et al. Biomarker correlates of survival in pediatric patients with ebola virus disease. Emerg Infect Dis. 2014;20:1683-1690.

100.  Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-737.

101.  Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196(suppl 2):S364-S371.

102.  Dickson SJ, Clay KA, Adam M, et al. Enhanced case management can be delivered for patients with EVD in Africa: experience from a UK military Ebola treatment centre in Sierra Leone. J Infect. 2018 Apr;76(4):383-392.

103.  Lamb L, Robson J, Ardley C, et al. Bacterial co-infection is rare in patients with Ebola virus disease in a military Ebola virus disease treatment unit in Sierra Leone. J Infect. 2015;71:406-407.

104.  Auffermann WF, Kraft CS, Vanairsdale S, et al. Radiographic imaging for patients with contagious infectious diseases: how to acquire chest radiographs of patients infected with the Ebola virus. AJR Am J Roentgenol. 2015;204:44-48.

105.  Butler D. Ebola experts seek to expand testing. Nature. 2014;516:154-155.

106.  Burd EM. Ebola virus: a clear and present danger. J Clin Microbiol. 2015;53:4-8.

107.  Hoenen T, Groseth A, Rosenke K, et al. Nanopore sequencing as a rapidly deployable ebola outbreak tool. Emerg Infect Dis. 2016;22:331-334.

108.  Tsang MK, Ye W, Wang G, et al. Ultrasensitive detection of ebola virus oligonucleotide based on upconversion nanoprobe/nanoporous membrane system. ACS Nano. 2016;10:598-605.

109.  Quick J, Loman NJ, Duraffour S, et al. Real-time, portable genome sequencing for Ebola surveillance. Nature. 2016;530:228-232.

110.  Semper AE, Broadhurst MJ, Richards J, et al. Performance of the GeneXpert Ebola assay for diagnosis of Ebola virus disease in Sierra Leone: a field evaluation study. PLoS Med. 2016;13:e1001980.

111.  Moshirfar M, Fenzl CR, Li Z. What we know about ocular manifestations of Ebola. Clin Ophthalmol. 2014;8:2355-2357.

112.  Food and Drug Administation. FDA authorizes emergency use of first Ebola fingerstick test with portable reader. November 2018 [internet publication].

113.  Public Health England. Marburg virus disease: origins, reservoirs, transmission and guidelines. September 2014. https://www.gov.uk/ (last accessed 19 July 2017).

114.  Public Health England. Crimean-Congo haemorrhagic fever: origins, reservoirs, transmission and guidelines. September 2016. https://www.gov.uk/ (last accessed 19 July 2017).

115.  Public Health England. Lassa fever: origins, reservoirs, transmission and guidelines. April 2017. https://www.gov.uk/ (last accessed 19 July 2017).

116.  Hensley LE, Wahl-Jensen V, McCormick JB, et al. Viral hemorrhagic fevers. In: Cohen J, Powderly W, Opal S, eds. Infectious Diseases. 3rd ed. Maryland Heights, MO: Mosby; 2010:1231-1237.

117.  Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17:494-501.

118.  Bah EI, Lamah MC, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40-47.

119.  Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394-2401.

120.  Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385:1428-1435.

121.  Lyon GM, Mehta AK, Varkey JB, et al; Emory Serious Communicable Diseases Unit. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402-2409.

122.  Parra JM, Salmerón OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med. 2014;371:2439-2440.

123.  Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374:636-646.

124.  Zacharowski K, Brodt HR, Wolf T. Medical treatment of an Ebola-infected doctor -ethics over costs? Lancet. 2015;385:685.

125.  Solano T, Gilbert GL, Kerridge IH, et al. Ethical considerations in the management of Ebola virus disease. Med J Aust. 2015;203:193-195.

126.  Jacobs M, Beadsworth M, Schmid M, et al. Provision of care for Ebola. Lancet. 2014;384:2105-2106.

127.  Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-737.

128.  Decker BK, Sevransky JE, Barrett K, et al. Preparing for critical care services to patients with ebola. Ann Intern Med. 2014;161:831-832.

129.  Canadian Critical Care Society; Canadian Association of Emergency Physicians; Association of Medical Microbiology and Infectious Diseases of Canada. Ebola clinical care guidelines: a guide for clinicians in Canada. October 2014. http://www.canadiancriticalcare.org/ (last accessed 19 July 2017).

130.  Olupot-Olupot P. Ebola in children: epidemiology, clinical features, diagnosis and outcomes. Pediatr Infect Dis J. 2015;34:314-316.

131.  Herberg JA, Emonts M, Jacobs M, et al. UK preparedness for children with Ebola infection. Arch Dis Child. 2015;100:421-423.

132.  Eriksson CO, Uyeki TM, Christian MD, et al. Care of the child with Ebola virus disease. Pediatr Crit Care Med. 2015;16:97-103.

133.  Lamontagne F, Fowler RA, Adhikari NK, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2018 Feb 17;391(10121):700-708.

134.  Rees PS, Lamb LE, Nicholson-Roberts TC, et al. Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. Intensive Care Med. 2015;41:735-743.

135.  Hunt L, Gupta-Wright A, Simms V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292-1299.

136.  Perner A, Fowler R, Bellomo R, et al. Ebola care and research protocols. Intensive Care Med. 2015;41:111-114.

137.  Roberts I, Perner A. Ebola virus disease: clinical care and patient-centred research. Lancet. 2014;384:2001-2002.

138.  Schieffelin JS, Shaffer JG, Goba A, et al; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092-2100.

139.  Clay KA, Johnston AM, Moore A, et al. Targeted electrolyte replacement in patients with Ebola virus disease. Clin Infect Dis. 2015;61:1030-1031.

140.  World Health Organization. Manual for the care and management of patients in Ebola care units/community care centres: interim emergency guidance. January 2015. http://www.who.int/ (last accessed 19 July 2017).

141.  Kendall RE, Gosser RA, Schulz LT, et al. Anti-diarrheal medication use in the treatment of Ebola virus-induced diarrhea. Travel Med Infect Dis. 2015;13:205-206.

142.  Chertow DS, Uyeki TM, DuPont HL. Loperamide therapy for voluminous diarrhea in Ebola virus disease. J Infect Dis. 2015;211:1036-1037.

143.  World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. February 2016. http://apps.who.int/ (last accessed 19 July 2017).

144.  Dickson SJ, Clay KA, Adam M, et al. Enhanced case management can be delivered for patients with EVD in Africa: experience from a UK military Ebola treatment centre in Sierra Leone. J Infect. 2018 Apr;76(4):383-392.

145.  Rhodes A, Evens LE, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-377.

146.  Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761-767.

147.  Fletcher T, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med. 2014;40:1936-1939.

148.  Connor MJ Jr, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26:31-37.

149.  World Health Organization. Interim guidance: potential Ebola therapies and vaccines. November 2014. http://apps.who.int/ (last accessed 19 July 2017).

150.  Kreil TR. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis. 2015;21:521-523.

151.  Gutfraind A, Myers LA. Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis. 2015;211:1262-1267.

152.  van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33-42.

153.  van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62:69-74.

154.  Mupapa K, Mukundu W, Bwaka MA, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999;179(suppl 1):S11-S12.

155.  Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa - clinical manifestations and management. N Engl J Med. 2014;371:2054-2057.

156.  Jamieson DJ, Uyeki TM, Callaghan WM, et al. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol. 2014;124:1005-1010.

157.  Association of Women's Health, Obstetric and Neonatal Nurses. Ebola: caring for pregnant and postpartum women and newborns in the United States: AWHONN practice brief number 3. J Obstet Gynecol Neonat Nurs. 2015;44:164-165.

158.  Kitching A, Walsh A, Morgan D. Ebola in pregnancy: risk and clinical outcomes. BJOG. 2015;122:287.

159.  Baggi FM, Taybi A, Kurth A, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill. 2014;19:20983.

160.  World Health Organization. Ebola treatments approved for compassionate use in current outbreak. June 2018 [internet publication].

161.  Rees PS, Lamb LE, Nicholson-Roberts TC, et al. Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit. Intensive Care Med. 2015;41:735-743.

162.  Lamontagne F, Fowler RA, Adhikari NK, et al. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet. 2018 Feb 17;391(10121):700-708.

163.  Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385:1428-1435.

164.  Clay KA, Johnston AM, Moore A, et al. Targeted electrolyte replacement in patients with Ebola virus disease. Clin Infect Dis. 2015;61:1030-1031.

165.  World Health Organization. Clinical management of patients with viral haemorrhagic fever: a pocket guide for the front-line health worker. February 2016. http://apps.who.int/ (last accessed 19 July 2017).

166.  World Health Organization. Interim guidance: potential Ebola therapies and vaccines. November 2014. http://apps.who.int/ (last accessed 19 July 2017).

167.  Kreil TR. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis. 2015;21:521-523.

168.  Gutfraind A, Myers LA. Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia. J Infect Dis. 2015;211:1262-1267.

169.  van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33-42.

170.  van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62:69-74.

171.  Rhodes A, Evens LE, Alhazzani W, et al. Surviving Sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-377.

172.  Canadian Critical Care Society; Canadian Association of Emergency Physicians; Association of Medical Microbiology and Infectious Diseases of Canada. Ebola clinical care guidelines: a guide for clinicians in Canada. October 2014. http://www.canadiancriticalcare.org/ (last accessed 19 July 2017).

173.  Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374:636-646.

174.  Connor MJ Jr, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol. 2015;26:31-37.

175.  Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761-767.

176.  Mupapa K, Mukundu W, Bwaka MA, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis. 1999;179(suppl 1):S11-S12.

177.  Jamieson DJ, Uyeki TM, Callaghan WM, et al. What obstetrician-gynecologists should know about Ebola: a perspective from the Centers for Disease Control and Prevention. Obstet Gynecol. 2014;124:1005-1010.

178.  Association of Women's Health, Obstetric and Neonatal Nurses. Ebola: caring for pregnant and postpartum women and newborns in the United States: AWHONN practice brief number 3. J Obstet Gynecol Neonat Nurs. 2015;44:164-165.

179.  Kitching A, Walsh A, Morgan D. Ebola in pregnancy: risk and clinical outcomes. BJOG. 2015;122:287.

180.  Baggi FM, Taybi A, Kurth A, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill. 2014;19:20983.

181.  Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother. 2015;49:196-206.

182.  Kouznetsova J, Sun W, Martínez-Romero C, et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect. 2014;3:e84.

183.  Kilgore PE, Grabenstein JD, Salim AM, et al. Treatment of Ebola virus disease. Pharmacotherapy. 2015;35:43-53.

184.  Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe - preliminary report. N Engl J Med. 2016;374:1647-1660.

185.  Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156-1166.

186.  Regules JA, Beigel JH, Paolino KM, et al; rVSVΔG-ZEBOV-GP Study Group. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med. 2017;376:330-341.

187.  Elsherif MS, Brown C, MacKinnon-Cameron D, et al; Canadian Immunization Research Network. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017;189:E819-E827.

188.  Conteh MA, Goldstein ST, Wurie HR, et al. Clinical surveillance and evaluation of suspected Ebola cases in a vaccine trial during an Ebola epidemic: the Sierra Leone trial to introduce a vaccine against Ebola. J Infect Dis. 2018 May 18;217(suppl_1):S33-S39.

189.  Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505-518.

190.  World Health Organization. Frequently asked questions on compassionate use of investigational vaccine for the Ebola virus disease outbreak in Democratic Republic of the Congo. May 2018 [internet publication].

191.  World Health Organization. World Health Organization. Ebola virus disease – Democratic Republic of the Congo: update on ring vaccination. May 2018 [internet publication].

192.  Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82:95-102.

193.  Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967.

194.  Warren T, Jordan R, Lo M, et al. Nucleotide prodrug GS-5734 is a broad-spectrum Filovirus inhibitor that provides complete therapeutic protection against the development of Ebola Virus Disease (EVD) in infected non-human primates. Late breaker abstract 2. Presented at IDWeek. San Diego, 2015. https://idsa.confex.com/ (last accessed 19 July 2017).

195.  Goodman JL. Studying "secret serums": toward safe, effective Ebola treatments. N Engl J Med. 2014;371:1086-1089.

196.  Zhang Y, Li D, Jin X, et al. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Sci China Life Sci. 2014;57:987-988.

197.  Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47-53.

198.  Davey RT Jr, Dodd L, Proschan MA, et al; PREVAIL II Writing Group; Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448-1456.

199.  ClinicalTrials.gov. Safety and pharmacokinetics of a human monoclonal antibody, VRC-EBOMAB092-00-AB (MAb114), administered intravenously to healthy adults. ClinicalTrials.gov identifier NCT03478891. July 2018 [internet publication].

200.  Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 2004;25:98-104.

201.  Winslow RL, Milligan ID, Voysey M, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored Ebola vaccines at 1 year. JAMA. 2017;317:1075-1077.

202.  Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017 Oct 12;377(15):1438-1447.

203.  Thi EP, Mire CE, Ursic-Bedoya R, et al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci Transl Med. 2014;6:250ra116.

204.  Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896-1905.

205.  Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013;27:565-583.

206.  Dunning J, Sahr F, Rojek A, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med. 2016;13:e1001997.

207.  Kugelman JR, Kugelman-Tonos J, Ladner JT, et al. Emergence of Ebola virus escape variants in infected nonhuman primates treated with the MB-003 antibody cocktail. Cell Rep. 2015;12:2111-2120.

208.  World Health Organization. Ebola vaccines, therapies, and diagnostics. October 2015. http://www.who.int/ (last accessed 19 July 2017).

209.  Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508:402-405.

210.  Hallen J, Petzelbauer P, Schwitter J, et al. Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial. EuroIntervention. 2010;5:946-952.

211.  Gröger M, Pasteiner W, Ignatyev G, et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PloS One. 2009;4:e5391.

212.  Iversen PL, Warren TK, Wells JB, et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses. 2012;4:2806-2830.

213.  Heald AE, Iversen PL, Saoud JB, et al. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrobial Agents Chemother. 2014;58:6639-6647.

214.  Gulland A. Clinical trials of Ebola therapies to begin in December. BMJ. 2014;349:g6827.

215.  BioSpace. Chimerix, Inc. (CMRX) abandons testing of experimental Ebola drug in Liberia. February 2015. http://www.biospace.com/ (last accessed 19 July 2017).

216.  Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ. 2014;349:g7198.

217.  Gupta-Wright A, Lavers J, Irvine S. Response to: Doctors trial amiodarone for Ebola in Sierra Leone. BMJ. 2014;349:g7198.

218.  Wandtke T, Woźniak J, Kopiński P. Aptamers in diagnostics and treatment of viral infections. Viruses. 2015;7:751-780.

219.  Picazo E, Giordanetto F. Small molecule inhibitors of Ebola virus infection. Drug Discov Today. 2015;20:277-286.

220.  WHO Ebola Response Team. Ebola virus disease among male and female persons in West Africa. N Engl J Med. 2016;374:96-98.

221.  Olupot-Olupot P. Ebola in children: epidemiology, clinical features, diagnosis and outcomes. Pediatr Infect Dis J. 2015;34:314-316.

222.  Herberg JA, Emonts M, Jacobs M, et al. UK preparedness for children with Ebola infection. Arch Dis Child. 2015;100:421-423.

223.  Eriksson CO, Uyeki TM, Christian MD, et al. Care of the child with Ebola virus disease. Pediatr Crit Care Med. 2015;16:97-103.

224.  Sadek RF, Khan AS, Stevens G, et al. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis. 1999;179(suppl 1):S24-S27.

225.  Lauck M, Bailey AL, Andersen KG, et al. GB virus C co-infections in West African Ebola patients. J Virol. 2015;89:2425-2429.

226.  Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survivors - final report. N Engl J Med. 2017 Oct 12;377(15):1428-1437.

227.  Soka MJ, Choi MJ, Baller A, et al. Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. Lancet Glob Health. 2016;4:e736-e743.

228.  Etard JF, Sow MS, Leroy S, et al; Postebogui Study Group. Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis. 2017;17:545-552.

229.  PREVAIL III Study Group, Sneller MC, Reilly C, et al. A longitudinal study of Ebola sequelae in Liberia. N Engl J Med. 2019 Mar 7;380(10):924-934.

230.  Chughtai AA, Barnes M, Macintyre CR. Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol Infect. 2016;144:1652-1660.

231.  Mattia JG, Vandy MJ, Chang JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis. 2016;16:331-338.

232.  Scott JT, Sesay FR, Massaquoi TA, et al. Post-Ebola syndrome, Sierra Leone. Emerg Infect Dis. 2016;22:641-646.

233.  Tiffany A, Vetter P, Mattia J, et al. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin Infect Dis. 2016;62:1360-1366.

234.  PREVAIL III Study Group, Sneller MC, Reilly C, et al. A longitudinal study of Ebola sequelae in Liberia. N Engl J Med. 2019 Mar 7;380(10):924-934.

235.  Shantha JG, Yeh S, Nguyen QD. Ebola virus disease and the eye. Curr Opin Ophthalmol. 2016;27:538-544.

236.  Shantha JG, Crozier I, Hayek BR, et al. Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia. Ophthalmology. 2017;124:170-177.

237.  Varkey JB, Shanth JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015;372:2423-2427.

238.  Chancellor JR, Padmanabhan SP, Greenough TC, et al. Uveitis and systemic inflammatory markers in convalescent phase of Ebola virus disease. Emerg Infect Dis. 2016;22:295-297.

239.  Steptoe PJ, Scott JT, Baxter JM, et al. Novel retinal lesion in Ebola survivors, Sierra Leone, 2016. Emerg Infect Dis. 2017;23:1102-1109.

240.  Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016 Jul 30;388(10043):498-503.

241.  Howlett P, Brown C, Helderman T, et al. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg Infect Dis. 2016 Jan;22(1):150-2.

242.  Dokubo EK, Wendland A, Mate SE, et al. Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. The Lancet Infectious Diseases. July 2018 [internet publication].

243.  Locsin RC, Barnard A, Matua AG, et al. Surviving Ebola: understanding experience through artistic expression. Int Nurs Rev. 2003;50:156-166.

244.  De Roo A, Ado B, Rose B, et al. Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health. 1998;3:883-885.

245.  World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. September 2014. http://apps.who.int/ (last accessed 19 July 2017).

246.  Wong KK, Davey RT Jr, Hewlett AL, et al. Use of post-exposure prophylaxis after occupational exposure to Zaire ebolavirus. Clin Infect Dis. 2016;63:376-379.

247.  Fischer WA Nd, Vetter P, Bausch DG, et al. Ebola virus disease: an update on post-exposure prophylaxis. Lancet Infect Dis. 2017 Nov 15. pii: S1473-3099(17)30677-1.

248.  Savini H, Ficko C, Simon F. Post-exposure prophylaxis in Ebola virus disease: don't forget the psychological factors. Lancet Infect Dis. 2018 Apr;18(4):378.

Use of this content is subject to our disclaimer